Prelude Therapeutics Inc (PRLD)
About Prelude Therapeutics Inc
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $12.1M
- Net income
- -$99.5M
- Total assets
- $141.3M
- Market cap
- $305.0M
- Operating margin
- -861.3%
- Net margin
- -819.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $12.1M
- Operating expenses
- $116.7M
- Operating income
- -$104.6M
- Income tax
- $0
- Net income
- -$99.5M
- EPS (basic)
- $-1.29
- EPS (diluted)
- $-1.29
Balance sheet
- Total assets
- $141.3M
- Current assets
- $105.7M
- Total liabilities
- $72.7M
- Current liabilities
- $53.0M
- Shareholders’ equity
- $68.6M
Cash flow
- Operating cash flow
- -$56.3M
- Investing cash flow
- $53.5M
- Financing cash flow
- $24.8M
- Net cash flow
- $22.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $305.0M
- EPS (diluted)
- $-1.29
- Shares outstanding
- 79.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 25, 2020
Prelude Therapeutics Inc (PRLD) Stock Price
- Reported a net loss of $99.5M in FY2025.
- Trading 31% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Prelude Therapeutics Inc.
Write a review
News about Prelude Therapeutics Inc
News & sentiment via Polygon.io
Prelude Therapeutics Inc: frequently asked questions
Is Prelude Therapeutics Inc an American company?
Prelude Therapeutics Inc is a US-based company headquartered in Wilmington, Delaware, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Prelude Therapeutics Inc headquartered?
Prelude Therapeutics Inc is headquartered in Wilmington, Delaware, United States.
Is Prelude Therapeutics Inc publicly traded?
Yes — Prelude Therapeutics Inc is a publicly traded company. Its stock trades under the ticker symbol PRLD on the NASDAQ.
What does Prelude Therapeutics Inc do?
Prelude Therapeutics Inc is an American Pharmaceuticals company in the Health & Beauty sector.
When was Prelude Therapeutics Inc founded?
Prelude Therapeutics Inc was founded in 2016.
